Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

Author's Avatar
Feb 07, 2023

NORTHVALE, NJ / ACCESSWIRE / February 7, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today reported positive results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites . IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product.